# Extensions - Onconova Implementation Guide v0.2.0

* [**Table of Contents**](toc.md)
* **Extensions**

## Extensions

Extensions The following extensions have been defined for this implementation guide:

* [Therapy Line Reference](StructureDefinition-ext-therapy-line-reference.md) 
A reference to the therapy line associated with this treatment. 

* [Adjunctive Role](StructureDefinition-onconova-ext-adjunctive-role.md) 
Indicates the role of this medication administration in the context of the overall treatment plan. 

* [Adverse Event Mitigation](StructureDefinition-onconova-ext-adverse-event-mitigation.md) 
Details about an action taken to mitigate or manage the adverse event. 

* [Age at Diagnosis](StructureDefinition-onconova-ext-age-at-diagnosis.md) 
The approximate age of the patient at the time of diagnosis of the disease. 

* [Age](StructureDefinition-onconova-ext-age.md) 
The approximate age of the patient. 

* [Cancer Morphology](StructureDefinition-onconova-ext-cancer-morphology.md) 
The morphology of the cancer, represented by a ICD-O-3 code. 

* [Cancer Topography](StructureDefinition-onconova-ext-cancer-topography.md) 
The topography of the cancer, represented by a ICD-O-3 code. 

* [Cause of Death](StructureDefinition-onconova-ext-cause-of-death.md) 
The cause of death for the patient. 

* [Combined With](StructureDefinition-onconova-ext-combined-with.md) 
Indicates that this medication administration was given in combination with another medication administration. 

* [Consent status](StructureDefinition-onconova-ext-consent-status.md) 
The status of whether the patient has given or revoked consent for reasearch use. 

* [Contributors](StructureDefinition-onconova-ext-contributors.md) 
The individuals or organizations that contributed to the patient's care. 

* [CTCAE Grade](StructureDefinition-onconova-ext-ctc-grade.md) 
The grade of the adverse event as defined by the Common Terminology Criteria for Adverse Events (CTCAE). 

* [Cycles](StructureDefinition-onconova-ext-cycles.md) 
Indicates the total number of cycles for this medication administration. 

* [Data Completion Rate](StructureDefinition-onconova-ext-data-completion-rate.md) 
The percentage of data elements categories that have been completed for a patient. 

* [Recurrence Type](StructureDefinition-onconova-ext-differentiation.md) 
THe histological differentiation of the tumor. 

* [End of Records](StructureDefinition-onconova-ext-end-of-records.md) 
Indicates the last known record date of a patient. 

* [Genomic Assessment Date](StructureDefinition-onconova-ext-genomic-assessment-date.md) 
Date at which the genomic variant was assessed and/or reported. 

* [Is Primary Therapy](StructureDefinition-onconova-ext-is-primary-therapy.md) 
Indicates whether this medication administration is the primary therapy within a therapy line. 

* [Molecular Tumor Board CUP Characterization](StructureDefinition-onconova-ext-molecular-tumor-board-cup-characterization.md) 
A characterization of the tumor board review focused on cancer of unknown primary (CUP) origin. 

* [Molecular Tumor Board Molecular Comparison](StructureDefinition-onconova-ext-molecular-tumor-board-molecular-comparison.md) 
A comparison of molecular findings discussed during the molecular tumor board review. 

* [Molecular Tumor Board Therapeutic Recommendation](StructureDefinition-onconova-ext-molecular-tumor-board-therapeutic-recommendation.md) 
A therapeutic recommendation or follow-up action resulting from a molecular tumor board review. 

* [Overall Survival](StructureDefinition-onconova-ext-overall-survival.md) 
The duration of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the overall survival is one way to see how well a new treatment works. 

* [Recist Is Interpreted](StructureDefinition-onconova-ext-recist-is-interpreted.md) 
Indicates that whether the RECIST was interpreted from a radiology report rather than extracted. 

* [Recurrence Of](StructureDefinition-onconova-ext-recurrence-of.md) 
Indicates that the condition is a recurrence of a previous condition, and provides a reference to that previous condition. 

* [Recurrence Type](StructureDefinition-onconova-ext-recurrence-type.md) 
Indicates the type of recurrence for the condition (local or regional). 

* [Risk Assessment Score](StructureDefinition-onconova-ext-risk-assessment-score.md) 
The numerical score of the risk assessment. 

* [Therapy Line Intent](StructureDefinition-onconova-ext-therapy-line-intent.md) 
The intent of the therapy line, such as curative or palliative. 

* [Therapy Line Number](StructureDefinition-onconova-ext-therapy-line-number.md) 
The number representing the sequence of the therapy line in the overall treatment regimen. 

* [Therapy Line Period](StructureDefinition-onconova-ext-therapy-line-period.md) 
The period during which the therapy line was performed. 

* [Therapy Line Progression Date](StructureDefinition-onconova-ext-therapy-line-progression-date.md) 
The date when disease progression was observed during or after the therapy line. 

* [Therapy Line Progression-Free Survival](StructureDefinition-onconova-ext-therapy-line-progression-free-survival.md) 
The progression-free survival duration for the therapy line. 

* [Tumor Board Specialization](StructureDefinition-onconova-ext-tumor-board-specialization.md) 
The specialization or focus area of the tumor board conducting the review, such as hematologic malignancies or solid tumors. 

* [Tumor Marker Analyte](StructureDefinition-onconova-ext-tumor-marker-analyte.md) 
The specific analyte or substance being measured as a tumor marker, such as PSA, CA-125, or CEA. 

* [Unknown Entry](StructureDefinition-onconova-ext-unknown-entry.md) 
Value is not collected and cannot be provided by Onconova. 

* [Vital status](StructureDefinition-onconova-ext-vital-status.md) 
The status of whether the patient is alive or deceased or unknown. 

